| George John Arcos, DO | |
|
4513 Executive Dr, Naples, FL 34119-9033 | |
| (239) 591-2803 | |
| (239) 594-5637 |
| Full Name | George John Arcos |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 41 Years |
| Location | 4513 Executive Dr, Naples, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255432878 | NPI | - | NPPES |
| 80033 | Other | FL | BLUECROSS BLUESHEILD |
| 383677550 | Other | FL | CAPITAL HEALTH PLAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | OS4651 (Florida) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | OS4651 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physiotherapy Associates Inc | 3577470442 | 429 |
| Korunda Medical, Llc | 5092895334 | 9 |
| Family Spine And Pain Care Institute Llc | 7517204555 | 2 |
| Nokomis Physical Therapy Llc | 8628240843 | 36 |
News Archive
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
Paralysis is often the result of nerve damage that prevents commands from the brain being relayed to muscle to cause movement...
According to a new report, every year an estimated 8 million children are born with a serious birth defect of genetic or partially genetic origin.
While a large number of women quit or reduce smoking upon pregnancy recognition, many resume smoking postpartum. Previous research has estimated that approximately 70% of women who quit smoking during pregnancy relapse within the first year after childbirth, and of those who relapse, 67% resume smoking by three months, and up to 90% by six months.
› Verified 1 days ago
| Entity Name | Korunda Medical, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609056282 PECOS PAC ID: 5092895334 Enrollment ID: O20071228000056 |
News Archive
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
Paralysis is often the result of nerve damage that prevents commands from the brain being relayed to muscle to cause movement...
According to a new report, every year an estimated 8 million children are born with a serious birth defect of genetic or partially genetic origin.
While a large number of women quit or reduce smoking upon pregnancy recognition, many resume smoking postpartum. Previous research has estimated that approximately 70% of women who quit smoking during pregnancy relapse within the first year after childbirth, and of those who relapse, 67% resume smoking by three months, and up to 90% by six months.
› Verified 1 days ago
| Entity Name | Xenon Health Of Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437524410 PECOS PAC ID: 3476859075 Enrollment ID: O20160308001547 |
News Archive
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
Paralysis is often the result of nerve damage that prevents commands from the brain being relayed to muscle to cause movement...
According to a new report, every year an estimated 8 million children are born with a serious birth defect of genetic or partially genetic origin.
While a large number of women quit or reduce smoking upon pregnancy recognition, many resume smoking postpartum. Previous research has estimated that approximately 70% of women who quit smoking during pregnancy relapse within the first year after childbirth, and of those who relapse, 67% resume smoking by three months, and up to 90% by six months.
› Verified 1 days ago
| Entity Name | Family Spine And Pain Care Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619442209 PECOS PAC ID: 7517204555 Enrollment ID: O20190129001052 |
News Archive
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
Paralysis is often the result of nerve damage that prevents commands from the brain being relayed to muscle to cause movement...
According to a new report, every year an estimated 8 million children are born with a serious birth defect of genetic or partially genetic origin.
While a large number of women quit or reduce smoking upon pregnancy recognition, many resume smoking postpartum. Previous research has estimated that approximately 70% of women who quit smoking during pregnancy relapse within the first year after childbirth, and of those who relapse, 67% resume smoking by three months, and up to 90% by six months.
› Verified 1 days ago
| Entity Name | Floridian Anesthesia Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598391195 PECOS PAC ID: 2860811536 Enrollment ID: O20200929003144 |
News Archive
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
Paralysis is often the result of nerve damage that prevents commands from the brain being relayed to muscle to cause movement...
According to a new report, every year an estimated 8 million children are born with a serious birth defect of genetic or partially genetic origin.
While a large number of women quit or reduce smoking upon pregnancy recognition, many resume smoking postpartum. Previous research has estimated that approximately 70% of women who quit smoking during pregnancy relapse within the first year after childbirth, and of those who relapse, 67% resume smoking by three months, and up to 90% by six months.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| George John Arcos, DO 4513 Executive Dr, Naples, FL 34119-9033 Ph: (239) 591-2803 | George John Arcos, DO 4513 Executive Dr, Naples, FL 34119-9033 Ph: (239) 591-2803 |
News Archive
Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.
Paralysis is often the result of nerve damage that prevents commands from the brain being relayed to muscle to cause movement...
According to a new report, every year an estimated 8 million children are born with a serious birth defect of genetic or partially genetic origin.
While a large number of women quit or reduce smoking upon pregnancy recognition, many resume smoking postpartum. Previous research has estimated that approximately 70% of women who quit smoking during pregnancy relapse within the first year after childbirth, and of those who relapse, 67% resume smoking by three months, and up to 90% by six months.
› Verified 1 days ago
Zdenko Korunda, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 4513 Executive Dr, Naples, FL 34119 Phone: 239-591-2803 Fax: 239-594-5637 | |
Gerald M Abraham, MD Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 11983 Tamiami Trl N Ste 120, Naples, FL 34110 Phone: 239-334-1478 Fax: 772-673-4623 | |
Paige Barber, Pain Medicine Medicare: Medicare Enrolled Practice Location: 4513 Executive Dr, Naples, FL 34119 Phone: 239-591-2803 | |
David A Pitts, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2338 Immokalee Rd Ste 203, Naples, FL 34110 Phone: 239-919-4342 |